ES2254047T3 - Procedimiento para la preparacion de derivados anticonvulsivos de topiramato. - Google Patents

Procedimiento para la preparacion de derivados anticonvulsivos de topiramato. Download PDF

Info

Publication number: ES2254047T3
Authority: ES; Spain
Prior art keywords: formula; baselineskip; compound; temperature; product
Prior art date: 2003-03-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04716438T

Other languages

English (en)

Spanish (es)

Other versions

ES2254047T1 (es

Inventor

Joachim Ernst Berkner

Scott Duncan

John Mills

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceuticals Inc

Original Assignee

Ortho McNeil Janssen Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-04

Filing date

2004-03-02

Publication date

2009-05-14

2004-03-02 Application filed by Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Ortho McNeil Janssen Pharmaceuticals Inc

2006-06-16 Publication of ES2254047T1 publication Critical patent/ES2254047T1/es

2009-05-14 Application granted granted Critical

2009-05-14 Publication of ES2254047T3 publication Critical patent/ES2254047T3/es

2024-03-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 56
238000002360 preparation method Methods 0.000 title claims abstract description 20
KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 title description 28
230000002082 anti-convulsion Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 73
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims abstract description 18
125000000217 alkyl group Chemical group 0.000 claims abstract description 15
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
239000001257 hydrogen Substances 0.000 claims abstract description 11
-1 methylenedioxy group Chemical group 0.000 claims abstract description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
150000002431 hydrogen Chemical class 0.000 claims abstract description 4
125000002009 alkene group Chemical group 0.000 claims abstract description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 56
PSSHGMIAIUYOJF-XBWDGYHZSA-N [(3as,5ar,8ar,8bs)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methanol Chemical compound C1O[C@@]2(CO)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PSSHGMIAIUYOJF-XBWDGYHZSA-N 0.000 claims description 36
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 28
239000003960 organic solvent Substances 0.000 claims description 10
150000007530 organic bases Chemical group 0.000 claims description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
238000006243 chemical reaction Methods 0.000 abstract description 25
230000008569 process Effects 0.000 abstract description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
239000000047 product Substances 0.000 description 45
239000000203 mixture Substances 0.000 description 36
239000011541 reaction mixture Substances 0.000 description 36
239000002904 solvent Substances 0.000 description 33
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 27
229960004394 topiramate Drugs 0.000 description 27
229940124530 sulfonamide Drugs 0.000 description 22
150000003456 sulfonamides Chemical class 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
239000010410 layer Substances 0.000 description 21
238000002474 experimental method Methods 0.000 description 20
239000008096 xylene Substances 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 11
FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 10
239000002253 acid Substances 0.000 description 10
238000002425 crystallisation Methods 0.000 description 10
230000008025 crystallization Effects 0.000 description 10
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
238000004821 distillation Methods 0.000 description 10
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 10
239000007788 liquid Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
229940078552 o-xylene Drugs 0.000 description 9
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000013078 crystal Substances 0.000 description 8
YSHMQTRICHYLGF-UHFFFAOYSA-N 4-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=NC=C1 YSHMQTRICHYLGF-UHFFFAOYSA-N 0.000 description 7
150000003738 xylenes Chemical class 0.000 description 7
YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
239000006286 aqueous extract Substances 0.000 description 6
150000003512 tertiary amines Chemical class 0.000 description 6
DJEQZVQFEPKLOY-UHFFFAOYSA-N N,N-dimethylbutylamine Chemical compound CCCCN(C)C DJEQZVQFEPKLOY-UHFFFAOYSA-N 0.000 description 5
URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 5
XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 5
238000000605 extraction Methods 0.000 description 5
IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 5
239000012071 phase Substances 0.000 description 5
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
229910020364 ClSO2 Inorganic materials 0.000 description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 3
125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 3
238000010915 one-step procedure Methods 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012360 testing method Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
OFYLHQMBVCAUSM-UHFFFAOYSA-N 2-tert-butyl-2-methyloxolane Chemical compound CC(C)(C)C1(C)CCCO1 OFYLHQMBVCAUSM-UHFFFAOYSA-N 0.000 description 1
UUIMDJFBHNDZOW-UHFFFAOYSA-N 2-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC=N1 UUIMDJFBHNDZOW-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 description 1
102100036186 Importin subunit alpha-5 Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
YUMNNMSNSLHINV-UHFFFAOYSA-N chloro sulfamate Chemical compound NS(=O)(=O)OCl YUMNNMSNSLHINV-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000007797 corrosion Effects 0.000 description 1
238000005260 corrosion Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
101150009274 nhr-1 gene Proteins 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

ES04716438T 2003-03-04 2004-03-02 Procedimiento para la preparacion de derivados anticonvulsivos de topiramato. Expired - Lifetime ES2254047T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45186303P	2003-03-04	2003-03-04
US451863P		2003-03-04

Publications (2)

Publication Number	Publication Date
ES2254047T1 ES2254047T1 (es)	2006-06-16
ES2254047T3 true ES2254047T3 (es)	2009-05-14

Family

ID=32962650

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES04716438T Expired - Lifetime ES2254047T3 (es)	2003-03-04	2004-03-02	Procedimiento para la preparacion de derivados anticonvulsivos de topiramato.

Country Status (26)

Country	Link
US (1)	US7157589B2 (pt)
EP (1)	EP1599490B8 (pt)
JP (1)	JP4725976B2 (pt)
KR (1)	KR20050119111A (pt)
CN (1)	CN100376591C (pt)
AR (1)	AR043466A1 (pt)
AT (1)	ATE421521T1 (pt)
AU (1)	AU2004217974A1 (pt)
BR (1)	BRPI0407967A (pt)
CA (1)	CA2517964A1 (pt)
CL (1)	CL2004000438A1 (pt)
DE (1)	DE602004019191D1 (pt)
DK (1)	DK1599490T3 (pt)
ES (1)	ES2254047T3 (pt)
HR (1)	HRP20050756A2 (pt)
MX (1)	MXPA05009384A (pt)
MY (1)	MY139235A (pt)
NO (1)	NO20054538L (pt)
NZ (1)	NZ541811A (pt)
PT (1)	PT1599490E (pt)
RU (1)	RU2333216C2 (pt)
SI (1)	SI1599490T1 (pt)
TW (1)	TW200504089A (pt)
UA (1)	UA81657C2 (pt)
WO (1)	WO2004078769A1 (pt)
ZA (1)	ZA200507995B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7638291B2 (en)	2004-10-25	2009-12-29	Seradyn, Inc.	Immunoassays for topiramate
US20060088886A1 (en) *	2004-10-25	2006-04-27	Anlong Ouyang	Topiramate analogs
WO2007099388A1 (en) *	2006-03-01	2007-09-07	Glade Organics Private Limited	An improved process for the manufacture of topiramate
WO2008010231A2 (en) *	2006-05-26	2008-01-24	Alembic Limited	A process for the purification of topiramate
US20090076128A1 (en) *	2007-09-15	2009-03-19	Protia Llc	Deuterium-enriched topiramate
WO2014037832A2 (en) *	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological disorders
US9399634B2 (en)	2012-05-07	2016-07-26	Cellix Bio Private Limited	Compositions and methods for the treatment of depression
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167992A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
US9321775B2 (en)	2012-05-10	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of moderate to severe pain
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168033A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
US9499527B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168016A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en)	2012-05-23	2016-11-15	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
NZ701832A (en)	2012-05-23	2016-08-26	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammatory bowel disease
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en)	2012-09-08	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammation and lipid disorders
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en)	2013-06-04	2015-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
NZ736131A (en)	2014-09-26	2019-04-26	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es)	2014-09-29	2020-12-16	Cellix Bio Private Ltd	Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja)	2014-10-27	2019-08-21	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
WO2016088132A1 (en)	2014-12-01	2016-06-09	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en)	2015-01-06	2017-08-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of inflammation and pain
CN106632530A (zh) *	2016-12-08	2017-05-10	陕西大生制药科技有限公司	高纯度托吡酯的制备方法
CN108341844A (zh) *	2018-04-25	2018-07-31	广州小桔生物科技有限公司	一种高纯度托吡酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513006A (en)	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US4582916A (en)	1983-09-26	1986-04-15	Mcneilab, Inc.	Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
IL103172A (en) *	1991-09-19	1997-01-10	Mcneilab Inc	Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
FR2704226B1 (fr) *	1993-04-22	1995-07-21	Sanofi Elf	3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2751334B1 (fr) *	1996-07-19	1998-10-16	Sanofi Sa	Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant

2004
- 2004-02-03 UA UAA200508358A patent/UA81657C2/ru unknown
- 2004-03-01 US US10/790,274 patent/US7157589B2/en not_active Expired - Lifetime
- 2004-03-02 KR KR1020057016420A patent/KR20050119111A/ko not_active Ceased
- 2004-03-02 BR BRPI0407967-1A patent/BRPI0407967A/pt not_active IP Right Cessation
- 2004-03-02 RU RU2005127626/04A patent/RU2333216C2/ru active
- 2004-03-02 SI SI200431098T patent/SI1599490T1/sl unknown
- 2004-03-02 ES ES04716438T patent/ES2254047T3/es not_active Expired - Lifetime
- 2004-03-02 CN CNB2004800057108A patent/CN100376591C/zh not_active Expired - Fee Related
- 2004-03-02 DE DE602004019191T patent/DE602004019191D1/de not_active Expired - Lifetime
- 2004-03-02 CA CA002517964A patent/CA2517964A1/en not_active Abandoned
- 2004-03-02 AU AU2004217974A patent/AU2004217974A1/en not_active Abandoned
- 2004-03-02 DK DK04716438T patent/DK1599490T3/da active
- 2004-03-02 PT PT04716438T patent/PT1599490E/pt unknown
- 2004-03-02 MX MXPA05009384A patent/MXPA05009384A/es active IP Right Grant
- 2004-03-02 AT AT04716438T patent/ATE421521T1/de not_active IP Right Cessation
- 2004-03-02 NZ NZ541811A patent/NZ541811A/en unknown
- 2004-03-02 EP EP04716438A patent/EP1599490B8/en not_active Expired - Lifetime
- 2004-03-02 WO PCT/US2004/006263 patent/WO2004078769A1/en not_active Ceased
- 2004-03-02 HR HR20050756A patent/HRP20050756A2/xx not_active Application Discontinuation
- 2004-03-02 JP JP2006508970A patent/JP4725976B2/ja not_active Expired - Fee Related
- 2004-03-03 MY MYPI20040728A patent/MY139235A/en unknown
- 2004-03-03 TW TW093105458A patent/TW200504089A/zh unknown
- 2004-03-04 AR ARP040100680A patent/AR043466A1/es not_active Application Discontinuation
- 2004-03-04 CL CL200400438A patent/CL2004000438A1/es unknown
2005
- 2005-10-03 ZA ZA200507995A patent/ZA200507995B/en unknown
- 2005-10-03 NO NO20054538A patent/NO20054538L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20054538L (no)	2005-10-03
BRPI0407967A (pt)	2006-03-07
PT1599490E (pt)	2009-04-03
CN100376591C (zh)	2008-03-26
MXPA05009384A (es)	2006-02-28
TW200504089A (en)	2005-02-01
ATE421521T1 (de)	2009-02-15
RU2005127626A (ru)	2006-01-27
US7157589B2 (en)	2007-01-02
EP1599490B1 (en)	2009-01-21
HK1088336A1 (zh)	2006-11-03
AR043466A1 (es)	2005-07-27
ES2254047T1 (es)	2006-06-16
WO2004078769A1 (en)	2004-09-16
UA81657C2 (ru)	2008-01-25
CL2004000438A1 (es)	2005-01-21
NZ541811A (en)	2008-07-31
JP4725976B2 (ja)	2011-07-13
CA2517964A1 (en)	2004-09-16
CN1756760A (zh)	2006-04-05
AU2004217974A1 (en)	2004-09-16
JP2006519860A (ja)	2006-08-31
EP1599490B8 (en)	2009-04-08
DK1599490T3 (da)	2009-04-27
US20040215004A1 (en)	2004-10-28
SI1599490T1 (sl)	2009-06-30
MY139235A (en)	2009-09-30
HRP20050756A2 (en)	2006-07-31
EP1599490A1 (en)	2005-11-30
DE602004019191D1 (de)	2009-03-12
KR20050119111A (ko)	2005-12-20
ZA200507995B (en)	2007-01-31
RU2333216C2 (ru)	2008-09-10

Publication	Publication Date	Title
ES2254047T3 (es)	2009-05-14	Procedimiento para la preparacion de derivados anticonvulsivos de topiramato.
KR101707246B1 (ko)	2017-02-15	고체 형태의 (2ｓ,3ｒ,4ｒ,5ｓ,6ｒ)-2-(4-클로로-3-(4-에톡시벤질)페닐)-6-(메틸티오)테트라히드로-2ｈ-피란-3,4,5-트리올 및 그의 사용 방법
EP3342777B1 (en)	2023-01-11	Benzyl compound
PL126667B1 (en)	1983-08-31	Method for producing new bis/n-(3,5-bis(hydroxyalkylaminocarbonyl)-2,4,6-triiodophenyl-n(alpha-hydroxyacyl))amino/alkanes
EP0340064B1 (fr)	1993-03-17	Benzodiazépines, leur procédé et intermédiaires de préparation et leurs applications en thérapeutique
EP0015038B1 (fr)	1984-12-19	Composition pharmaceutique comprenant un dérivé de diphénylhydantoine, dérivés mis en oeuvre et leur préparation
JP6066986B2 (ja)	2017-01-25	ｓ−トリアジン化合物の調製方法
WO2013190103A1 (de)	2013-12-27	Sialinsäurederivate
ES2858585T3 (es)	2021-09-30	Método y producto intermedio para preparar tulatromicina
EP4499830A1 (en)	2025-02-05	Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents
ES2619403T3 (es)	2017-06-26	Proceso para producir lacosamida
ES2655655T3 (es)	2018-02-21	Procedimiento de preparación de compuestos de alfa-galactosil ceramidas
DK164855B (da)	1992-08-31	Spergualin-beslaegtede forbindelser med en phenylengruppe, fremgangsmaade til fremstilling deraf samt en farmaceutisk sammensaetning
ES2259909B1 (es)	2007-06-16	Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis.
ES2260673T3 (es)	2006-11-01	Procedimiento continuo para la preparacion de derivados de sulfamato de fructopiranosa.
ES2992696T3 (en)	2024-12-17	Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-,(1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product
JPH0140027B2 (pt)	1989-08-24
SI9300365A (en)	1994-03-31	New alkenes and alkines phoshat derivates, process for their preparation and use thereof as medicine
KR20130140041A (ko)	2013-12-23	Pet 전구체의 제조
HK1088336B (en)	2008-06-20	Process for the preparation of anticonvulsant derivatives of topiramate
JPH02250899A (ja)	1990-10-08	ムラミルトリペプチド誘導体の製造法
WO1998023626A1 (de)	1998-06-04	Antiadhäsive benzoesäure-derivate
JPS60136591A (ja)	1985-07-20	グリコシド系化合物の製造法
JPS58135892A (ja)	1983-08-12	セフアロスポリン誘導体